ComplyAdvantage Announces ComplyLaunch™
27.4.2021 08:00:00 EEST | Business Wire | Press release
ComplyAdvantage, a global data technology company transforming financial crime detection, today announced a new early-stage anti-money laundering (AML) program aimed at growth-focused startups called ComplyLaunch™. The program provides qualified startups with free access to the company’s award-winning AML and Know Your Customer (KYC) tools and resources needed to uncover and reduce the threat of money-laundering activities so they can onboard new customers with lower risk and greater trust.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210426005376/en/
Charles Delingpole, CEO and Founder of ComplyAdvantage (Photo: Business Wire)
In addition, ComplyAdvantage has partnered with the global financial crime compliance consultancy FINTRAIL to provide AML education and ongoing training for program participants. FINTRAIL is a recognised authority on financial crime prevention in financial technology (FinTech) and the application of regulatory technology (RegTech), working with industry leading clients across the globe to transform, build, scale, and assure AFC compliance frameworks that are relevant for digital products.
Why ComplyLaunch, Why Now?
The impetus for the program was to prepare startups to take on one of the biggest challenges their businesses will face, which is money-laundering. If transacting startups want to maximize their competitive advantage with new or expanded services, then they need intelligent AML and risk management data solutions to prevent the unintended consequences from unknowingly onboarding criminal entities.
As a serial entrepreneur, ComplyAdvantage founder and CEO Charles Delingpole has experienced first-hand the many challenges that startup teams face and that the early-stage prevention of money-laundering shouldn’t be one of them. As such, Delingpole believes that providing free access to ComplyAdvantage’s AML tools will allow more fintech startups to reach success faster by reducing the business exposure due to unforeseen financial crimes.
“At ComplyAdvantage, we believe that free early access to AML tools and education on setting up a compliance program is a benefit to our entire fintech ecosystem,” said Charles Delingpole, founder and CEO of ComplyAdvantage. “By democratising access to best in class financial crime prevention tools, we are allowing fintech startups to not only match but exceed the compliance program standards of the largest, most regulated banks. ComplyLaunch is a very important program designed to maintain the integrity of Fintech insurgents by reducing the growing threat of financial crimes.”
The first startups to join ComplyLaunch include trustshare, a company that’s revolutionising escrow payments and Juno a company that delivers comprehensive solutions to integrate multi-channel payment services with ERPs and e-Commerce platforms.
“Because we’re focused on simplifying bank payments between friends, family, customers and businesses it made complete sense for our team to join the ComplyLaunch program,” said Pete Bailey, founder and CPO of Juno. “Partnering with ComplyAdvantage to implement their gold-standard AML detection solution means that we can on-board customers with greater confidence.”
Those early-stage fintech startups with no institutional funding are invited to apply for the program. To apply, applicants must meet the following criteria:
● Less than $1M in annual revenue
● Pre-seed - Seed stage
● A company website or web profile
● Less than 10 years old
“We’re excited to join as a launch partner for ComplyLaunch and to provide program members with access to our world-class AML training”, said James Nurse, Managing Director of FINTRAIL EMEA. “There are future fintech unicorns waiting to grow and early money-laundering and risk prevention resources will only help them to reach their success, faster.”
As a sign of growing community interest, the ComplyLaunch program will be promoted with the support of world-class organizations including the leading talent investor Entrepreneur First and Seccl an innovative technology platform providing outsourced custody for financial services firms looking to safeguard their clients' assets.
"There has never been a greater time to start a fintech company and we've seen more and more of the world's most ambitious people wanting to startup in this space,” said Jonny Clifford, of Entrepreneur First. “With the growing complexity of financial service interdependencies, ComplyLaunch is a great idea at the perfect time to help these emerging, disruptive fintech startups to scale more easily and more confidently.”
And finally, Max Rimple a Principal at Index Ventures and a lead investor in ComplyAdvantage also shared his thoughts on the program launch, "with the staggering amount of investment capital going into fintech and related financial services, it's important that startups have early access to intelligent AML and risk management tools so they can grow with integrity and confidence. The ComplyLaunch program is a great starting point for fintech founders to safeguard their businesses from the risks of financial crimes. It's also good for their investors who appreciate that early compliance practices help to set the stage for future success."
ComplyAdvantage offers a true hyperscale financial risk insight and AML data solution that leverages machine learning and natural language processing to help regulated organizations manage their risk obligations and prevent financial crime. The company’s proprietary database is derived from millions of data points that provide dynamic, real-time insights across sanctions, watchlists, politically exposed persons, and negative news. This reduces dependence on manual review processes and legacy databases by up to 80% and improves how companies screen and monitor clients and transactions.
ENDS
About ComplyAdvantage
ComplyAdvantage is the financial industry’s leading source of AI-driven financial crime risk data and detection technology. ComplyAdvantage’s mission is to neutralize the risk of money laundering, terrorist financing, corruption, and other financial crime. More than 500 enterprises in 75 countries rely on ComplyAdvantage to understand the risk of who they’re doing business with through the world's only global, real-time database of people and companies. The company actively identifies tens of thousands of risk events from millions of structured and unstructured data points every single day.
ComplyAdvantage has four global hubs located in New York, London, Singapore and Cluj-Napoca and is backed by Ontario Teachers’, Index Ventures and Balderton Capital. Learn more at complyadvantage.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005376/en/
Contact information
For ComplyAdvantage:
North America
Tim Donovan
+1.510.593.0064
Tim.Donovan@ComplyAdvantage.com
EMEA
Ben Goldsmith
+44.0.7788.295321
ben@goldsmithcomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
